MentalHealth.com Acquires Provider of Mental Health Resources and Clinical Guidelines
Founded in 1996, PsychGuides.com has been a longstanding provider of research-based mental health information, serving clinicians, policymakers, and patient advocates. Committed to advancing evidence-based care, it has collaborated with leading organizations, including Abbott Laboratories, Janssen Pharmaceutica, Solvay Pharmaceuticals, and Bristol Myers Squibb, to develop and distribute practical clinical guidelines that enhance mental health treatment and decision making.
'As mental health faces a pivotal moment driven by unprecedented demand, investing in high-quality resources that support informed decisions is essential to helping people regain well-being,' said Daniel Rivette, CEO and Co-Founder of MentalHealth.com. 'By integrating its guidelines and research-backed content into our platform, PsychGuides.com further enhances our reach and deepens our connection with those seeking support.'
This acquisition builds on a series of milestones for MentalHealth.com, including the acquisition of MentalHelp.net, the introduction of the MentalHealth.com Wellness Portal, and the launch of the Mental Health Network.
In the coming months, MentalHealth.com will announce key partnerships and acquisitions, along with new additions to its Venture Advisory, Clinical Affairs, and Public Oversight Teams, further reinforcing its mission to develop the world's most intelligent mental health technology.
To learn more about MentalHealth.com and its vision to support the mental health of one billion people, please visit: https://www.mentalhealth.com/vision
About MentalHealth.com
MentalHealth.com is a health technology company guiding people towards self-understanding and connection. The platform provides reliable resources, accessible services, and nurturing communities. Its purpose is to educate, support, and empower people in their pursuit of well-being.
Contact InformationHelena Georgiou 1-800-834-8587
SOURCE: MentalHealth.com, LLC
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
6 days ago
- Indianapolis Star
GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases
Phase 1 results demonstrate that SUL-238, a first-in-class, orally administered, mitochondria-directed drug candidate, is safe and well-tolerated in healthy elderly volunteers, showing a favourable pharmacokinetic profile and high brain penetration. These findings support the advancement of SUL-238 into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / July 28, 2025 / GEN Pharmaceuticals ( Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC ®) in Toronto. This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20). The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease. No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (C max) and area under the plasma concentration-time curve (AUC 0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%). Abidin Gülmüş, Chairman of GEN, stated: 'We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease.' Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added: 'With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease.' About SUL-238 SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's 'powerhouse.' It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications. About GEN: Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments. About Sulfateq: Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health. Contact Information Bulutay Güneş Sr. Head of Corporate Brand Ali Ketencioğlu Investor Relations Manager Kees van der Graaf Sulfateq CEO View the original press release on ACCESS Newswire The post GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases appeared first on DA80 Hub.
Associated Press
25-07-2025
- Associated Press
Primus Sounds Alarm on Chronic Venous Insufficiency as President Trump's Diagnosis Sparks National Focus
SCOTTSDALE, ARIZONA / ACCESS Newswire / July 24, 2025 / Following reports of President Donald J. Trump's diagnosis with Chronic Venous Insufficiency (CVI), Primus Pharmaceuticals, Inc. strongly calls on healthcare providers to intensify efforts to diagnose and treat this silent epidemic affecting 25-30 million Americans because only less than <10% are actually treated. Leg swelling, heaviness, and varicose veins are often dismissed as cosmetic or 'normal aging,' while they can signal a dangerous progression toward severe complications including thromboembolism (blood clots), debilitating pain, non-healing leg ulcers, and compromised mobility. Widespread, Under-Recognized Health Threat Life-Changing Solution: Vasculera® Primus offers Vasculera, the only U.S. prescription product for CVI. It is specifically formulated as a medical food for the clinical dietary management of CVI. Taken once daily, this 600mg tablet delivers highly purified, bioavailable diosmin, a flavonoid sourced from oranges, in combination with a pH buffering agent and: Manufactured in the U.S., Vasculera presents a novel naturally-derived alternative to the status quo. Expert Physician Perspectives 'CVI and its manifestation in skin known as stasis dermatitis is a very common condition that can lead to significant impairment and morbidity,' said Dr. Mark Nestor, MD, PhD, Board-certified Dermatologist and Voluntary Professor, Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine. 'Diosmin in its bioavailable form in the pharmaceutical-grade medical food Vasculera is a natural flavonoid that has scientifically proven benefit for this condition.' Board-certified Vascular Surgeon Dr. Ron Bush, MD, FACS, one of the world's foremost experts in the histology and treatment of venous disease states, 'CVI is a common condition, with symptoms that may vary but are consistently linked to elevated venous pressure. In my clinical experience, Vasculera has proven to be an effective treatment option. Its active ingredient, diosmin, is well-studied and widely documented for its ability to address the inflammation associated with chronic venous hypertension. Vasculera is also well-tolerated and has no significant contraindications.' Robust Clinical Backing Public Health Call to Action With an aging population and more time on electronic devices fueling CVI's prevalence, Primus urges clinicians to: For prescribing information, visit About Primus Pharmaceuticals Primus innovates in prescription nutritional therapies targeting metabolic causes of chronic diseases across rheumatology, dermatology, and women's health. We develop and commercialize first-in-class products and novel deliveries in Rx drugs, medical foods, and medical devices to fill key unmet needs with universal patient access not provided by traditional pharma. Visit Contact InformationRandy Keating Public Relations Manager 4802460509 SOURCE: Primus Pharmaceuticals press release
Associated Press
24-07-2025
- Associated Press
CDx Diagnostics Receives FDA Breakthrough Device Designation for Its WATS3D Test System for Esophageal Cancer
Novel AI-powered laboratory test for diagnosis of Barrett's esophagus, with or without dysplasia SUFFERN, NEW YORK / ACCESS Newswire / July 24, 2025 / CDx Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its proprietary WATS3D diagnostic system, a 'first-of-a-kind' AI-powered digital pathology system using wide area transepithelial sampling for the diagnosis of Barrett's esophagus and early neoplastic alterations in patients at risk for disease progression. 'The Breakthrough Device Designation recognizes what the volume of clinical data has shown: the WATS3D Test improves the ability to detect dysplasia in Barrett's esophagus, offering patients and physicians an improved method of detection of patients at risk of development of esophageal cancer,' said Robert Odze, MD, a leading gastrointestinal pathologist. To meet the requirements for FDA Breakthrough Device Designation, CDx Diagnostics submitted technical and clinical evidence from large multi-center studies showing that the WATS3D Test is 'more effective' than the Seattle biopsy protocol for the diagnosis of Barrett's esophagus, dysplasia and esophageal cancer. 'With data from greater than 23,000 patients, the WATS3D Test continues to demonstrate its potential to detect early-stage neoplastic disease that might be missed with conventional biopsies,' said Karen Hoffman, MD, Director of R&D at CDx Diagnostics. 'This designation recognizes the science behind our platform and supports our ongoing efforts to improve early detection of patients at risk.' The WATS3D Test System leverages proprietary artificial intelligence (AI) enabled algorithm for analysis of high-resolution digital pathology using novel 3-dimensional images from specimens collected using the WATS3D brush to identify precancerous and cancerous cells and assess the risk of progression to cancer. The WATS3D System was developed by CDx Diagnostics and is performed in the company's CLIA-certified, CAP accredited, New York state licensed clinical laboratory in Suffern, NY. For more information, visit or contact us at [email protected]. About CDx Diagnostics CDx Diagnostics' mission is to Empower Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time. CDx Diagnostics is changing the landscape of cancer prevention and diagnosis through innovative AI-driven digital pathology solutions developed and performed in the company's CLIA-certified, CAP accredited clinical laboratory in Suffern, New York. The company's first advanced diagnostic test- the WATS3D Test system powered by the WATS3D Esophageal AI Algorithm - has FDA Breakthrough Device Designation for the diagnosis of Barrett's esophagus (BE), with and without dysplasia. About the WATS3D Test System The WATS3D Test system is an AI-powered digital pathology test system that helps prevent the progression of neoplasia via more effective identification of Barrett's esophagus (BE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and esophageal adenocarcinoma (EAC). Developed and performed by CDx Diagnostics, the WATS3D Test leverages artificial intelligence (AI) enabled analysis using the WATS3D Esophageal AI Algorithm and 3D digital imaging of samples collected using a WATS3D brush to identify precancerous and cancerous cells and evaluate the risk of progression to cancer. The WATS3D Test has been used to analyze over 400,000 patient samples to identify those requiring earlier intervention, reduce time to treatment, and improve patient outcomes. Contact Information William Standwill Marketing [email protected] 845-777-7000 SOURCE: CDx Diagnostics press release
